Schrödinger, Inc. reports developments tied to its computational platform for molecular discovery, which is licensed to biotechnology, pharmaceutical, industrial and academic customers for drug development and materials design. Company updates commonly cover Software segment performance, hosted and license-server delivery, annual contract value, and the role of software revenue in the business.
News also addresses Schrödinger's Drug Discovery segment, including collaborative and internal programs, together with clinical or regulatory disclosures when applicable. Recurring corporate items include quarterly and annual financial results, investor conference participation, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), shareholder voting matters, governance changes and capital-structure disclosures.
Schrödinger (SDGR) granted restricted stock units covering 2,243 shares of common stock to three newly hired employees on September 13, 2026.
The awards were issued under the company’s 2021 Inducement Equity Incentive Plan and approved by the compensation committee as a material inducement to employment in line with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years: 25% after 12 months of continuous service from the vesting commencement date, with the remaining 75% vesting in three equal annual installments upon completion of each additional year of service. The grants remain subject to the terms of individual award agreements and the 2021 Inducement Equity Incentive Plan.
Schrödinger (SDGR) co-founded Tectora Therapeutics with New Enterprise Associates and RA Capital Management and licensed two early-stage immunology and inflammation programs to the new company.
Tectora concurrently closed a $55 million Series A investment from NEA and RA Capital. Schrödinger contributed small-molecule programs SDGR-4594 and SDGR-8139 in exchange for an equity stake in Tectora and eligibility for future milestones and royalties. Tectora will collaborate with Schrödinger’s drug discovery team and use Schrödinger’s computational platform at scale to advance these programs toward clinical candidates. Schrödinger highlights that similar partnerships, including Nimbus, Morphic, Structure and Ajax, have together generated over $750 million in proceeds to the company.
Schrödinger (Nasdaq: SDGR) announced that its management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The live presentation is scheduled for Monday, September 14, 2026 at 1:05 p.m. E.T. and will be available via live webcast in the Investors section of Schrödinger’s website, with an archive accessible for approximately 90 days.
Schrödinger (Nasdaq: SDGR) granted restricted stock units covering 3,315 common shares on August 12, 2026 to two newly hired employees under its 2021 Inducement Equity Incentive Plan. The RSUs serve as a material inducement to employment and vest over four years, subject to continuous service and plan terms.
Schrödinger (Nasdaq: SDGR) reported second quarter 2026 ACV of $29.6 million, up 27% year over year and $208 million on a trailing four-quarter basis. ACV excluding contribution was $22.6 million, up 23%. Total revenue rose 8% to $58.9 million, with software revenue of $32.5 million (down 10%) and drug discovery revenue of $23.0 million, reflecting a $10 million collaboration milestone tied to the Ajax Therapeutics acquisition. Contribution revenue was $3.4 million. Software gross margin was 71%, operating expenses declined 6% to $74.0 million, and other income reached $48.9 million, largely from Eli Lilly’s acquisition of Ajax Therapeutics.
Net income was $6.0 million versus a $43.2 million loss a year earlier, and cash, cash equivalents, restricted cash and marketable securities totaled $418.8 million. For 2026, Schrödinger expects ACV of $218–$228 million (10–15% growth) and raised drug discovery revenue guidance to $65–$75 million. The company launched early access to Bunsen, its agentic AI co-scientist, signed a Bunsen-focused software agreement with Bristol Myers Squibb, and entered a global discovery collaboration with Simcere, alongside publishing new validation research for its FEP+ and cryptic-binding-site workflows.
Schrödinger (Nasdaq: SDGR) announced a strategic collaboration and software agreement with Bristol Myers Squibb (BMS) to deploy Bunsen, Schrödinger’s agentic AI co-scientist, across BMS’s research organization. The deal builds on BMS’s long-standing use of Schrödinger’s computational platform.
Under the agreement, Schrödinger will work with BMS scientists to develop new Bunsen functionality integrated with its physics‑based molecular discovery technologies and with RetroSynth, its AI-driven synthesis planning platform. Bunsen is optimized to run Schrödinger’s validated computational methods, plan and execute complex molecular discovery workflows, and interpret results, enabling broader chemical exploration, higher-confidence molecule prioritization, and more “predict‑first” research decisions.
Schrödinger (Nasdaq: SDGR) launched an early access version of Bunsen, an agentic AI co-scientist for molecular discovery that combines AI with the company’s physics-based simulation platform. Bunsen is designed to help researchers understand scientific objectives, design computational strategies, execute complex discovery workflows and interpret molecular modeling results.
According to Schrödinger, Bunsen can evaluate more hypotheses, expand concurrent research sessions and make advanced methods accessible to non-computational chemists. The company is collaborating with NVIDIA and Google Cloud to provide a co-engineered full stack AI platform, including NVIDIA BioNeMo Agent Toolkit and RTX PRO 6000 Blackwell Server Edition GPUs on Google Cloud. Early access is limited to select customers, with full commercial release targeted by the end of 2026.
Schrödinger (Nasdaq: SDGR) will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after market close. The company will hold a conference call and webcast at 4:30 p.m. ET, accessible via the Investors section of its website, with an archive available for about 90 days.
Schrödinger (Nasdaq: SDGR) reported that on July 16, 2026, it granted restricted stock units (RSUs) covering 3,691 shares of common stock to four newly hired employees. The awards were issued under the company’s 2021 Inducement Equity Incentive Plan as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
According to Schrödinger, the RSUs vest over four years: 25% after 12 months of continuous service from the vesting commencement date, with the remaining 75% vesting in three equal annual installments, subject to the applicable award agreements and the plan terms.
Schrödinger (Nasdaq: SDGR) granted restricted stock units covering 10,771 shares to seven newly hired employees on June 12, 2026, under its 2021 Inducement Equity Incentive Plan.
The RSUs vest over four years, beginning after 12 months of continuous service, consistent with Nasdaq Listing Rule 5635(c)(4).